
OLR Bill Analysis

SB 80

AN ACT CONCERNING THE SHORTAGE OF CERTAIN DRUGS PRESCRIBED TO TREAT TYPE II DIABETES.

SUMMARY

This bill requires the consumer protection commissioner to adopt regulations to ensure that there is a sufficient supply of dulaglutide and semaglutide to treat patients in the state with type II diabetes. The bill specifies that the regulations may, among other things, prohibit pharmacists from dispensing these medications off-label while the drug is in short supply in Connecticut (see BACKGROUND).

EFFECTIVE DATE: Upon passage

BACKGROUND

Dulaglutide and Semaglutide Supply Shortage

Certain of these drugs, which are approved by the FDA for type II diabetes treatment, are currently included on the FDA's Drug Shortages list. Global demand for this class of drugs rose after clinical trials showed they provide weight loss benefits when prescribed off-label to non-diabetic patients.

COMMITTEE ACTION

General Law Committee

Joint Favorable

Yea 23 Nay 0 (03/02/2023)